AstraZeneca Merck Get FDA\'s ODD For Lynparza For Pancreatic Cancer

AstraZeneca, Merck Get FDA's ODD For Lynparza For Pancreatic Cancer

02:34 EDT 16 Oct 2018 | FinanzNachrichten

LONDON (dpa-AFX) - British drug major AstraZeneca (AZN.L, AZN) and Merck & Co., Inc., (MRK) announced Tuesday that they were granted orphan drug designation or ODD by the US Food and Drug Administ...

Original Article: AstraZeneca, Merck Get FDA's ODD For Lynparza For Pancreatic Cancer

More From BioPortfolio on "AstraZeneca, Merck Get FDA's ODD For Lynparza For Pancreatic Cancer"